Harmony Biosciences Holdings, Inc. Q3 2025 Earnings Recap

HRMY Q3 2025 November 5, 2025

Get alerts when HRMY reports next quarter

Harmony Biosciences reported a strong third quarter in 2025, achieving $239.5 million in net revenue—a 29% year-over-year increase—while raising its revenue guidance for the year.

Earnings Per Share Miss

$0.87 vs $0.92 est.

-5.4% surprise

Revenue Miss

239455000 vs 240036170 est.

-0.2% surprise

Market Reaction

1-Day +2.05%

5-Day +3.58%

30-Day +14.88%

See HRMY alongside your other holdings

Add to your portfolio — free

Key Takeaways

Record patient additions for WAKIX, averaging 8,100 patients, a significant increase of 500 patients this quarter.
Q3 net revenue guidance raised from $820 million to a new range of $845 million to $865 million, driven by strong commercial performance.
Robust cash generation of $106 million, increasing total cash reserves to $778 million.
Harmony is poised for future growth with ongoing development of its late-stage pipeline, including multiple upcoming catalyst events.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit HRMY on AllInvestView.